Its time for the final push.
With only a handful of trading weeks remaining in 2017, little stands in the way of higher prices.
This years stock market melt-up has produced a long list of incredible winners. The FAANGs, semiconductors, and other big tech stocks have helped fuel the rally. Weve also had multiple chances to profit from the big biotech comeback and the rebirth of homebuilder....More>>>
Bio-Techne Corp (NASDAQ:TECH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Bio-Techne Corp has a market cap of $4.5 billion; its shares were traded at around $120.62 with a P/E ratio of 62.16 and P/S ratio of 8.35.....More>>>
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of “3 Things In Biotech” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Shire enters the home stretch with its newer formulation of asparaginase
The stock market finished mixed on Tuesday, and although the Dow Jones Industrials still finished with a loss of more than 100 points, other major market benchmarks finished very close to the unchanged level on the day. Geopolitical pressure continued to hurt investor sentiment, and some bad news on the earnings front also cast a pall on trading during the regular session. Yet some stocks managed....More>>>
On Tuesday, Baird predicted that Gilead Sciences (GILD) will miss earnings forecasts when it releases its financials on April 28. Barclays’ Geoff Meacham and team, however, foresee an earnings beat from Gilead and Amgen (AMGN) as well, but are more cautious on Biogen (BIIB) and Celgene (CELG). They explain why:
Large-Cap Biotechs Strength in Gilead and Amgen. We think....More>>>
The Dow Jones Industrial Average came close to hitting 20,000, but fell short again…nearly four weeks after Barron’s wrote about the possibility in a cover story on Dec. 10.
The S&P 500 rose 0.4% to 2,276.98 today, a record high. The Nasdaq Composite, meanwhile, gained 0.6% to 5,521.06, also a record. The Dow Jones Industrial Average advanced 64.51 points,....More>>>
Investment company Harbour Capital Advisors, LLC buys iShares Core MSCI Emerging Markets, iShares Core MSCI EAFE, PIMCO Enhanced Short Maturity Active Exchange-Trad, iShares Nasdaq Biotechnology Index Fund, First Republic Bank, Chubb, Andeavor, Moelis, Charles Schwab Corp, NetEase Inc, sells MetLife Inc, Affiliated Managers Group Inc, Microchip Technology Inc, Nike Inc, Wells Fargo during the 3-months....More>>>
On Dec. 15, 2017, the share of Omeros Corporation (NASDAQ:OMER) – a bioscience focusing on the innovation and commercialization of drugs to treat complement-mediated diseases, inflammation, and central nervous system disorders – appreciated $0.47 to trade at $19.68 for 3.52% profits (as of 2:47 pm ET). Since we featured the firm in the Integrated BioSci Interview with....More>>>
Incyte (INCY) spent much of last year being on my attractive but overvalued list, but recent weakness in the biotech sector and other negative company specific factors led to a drastic sell-off. Now that the valuation is depressed, it is time to see if this has become an ROTY opportunity or if there is further downside ahead.
INCY data by YCharts
The year got off to a good start,....More>>>
There are few words in the English language that are hated more than “cancer.” And as far as public health dangers go, it’s one of the biggest enemies anyone could imagine.
According to the World Health Organization (WHO), cancer is one of the leading causes of mortality in the world — it’s responsible for nearly 1 in 6 deaths. And the danger isn’t going....More>>>